RUSH

Department of Ophthalmology Research Studies 2020-2021

Study/Network	Principal Investigator	Summary/Description	Enrollment
APELLIS	MacCumber	***A phase 3, multicenter, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).*** Primary Objective is to evaluate the efficacy of APL-2 compared to sham injection in patients with GA secondary to AMD assessed by change in the total area of GA lesions from baseline as measured by fundus autofluorescence (FAF). 4 subjects currently enrolled	**Enrollment complete**
ADVISE	Merrill	***Adalimumab vs. conventional Immunosuppression for Uveitis Trial.*** Treatment of non-infectious, intermediate, posterior, panuvetitis. Adalimumab OR conventional immunosuppressive therapy. Randomized.	**Currently Enrolling**
MERIT	Merrill	***Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT)***. This study will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.	**Currently Enrolling**
ZEDS	Rubenstein	***Zoster Eye Disease Study (ZEDS).*** A multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.	**Currently Enrolling**
FUCHS	Rubenstein	***A double-masked, randomized, placebo-controlled, parallel-group, 12-week study to investigate the safety and efficacy of ripasudil (K-***	**Enrollment to commence in near future**

		321) eye drops after descemetorhexis in patients with Fuchs endothelial corneal dystrophy This is a multi-center, double-masked, randomized, parallel-group controlled 2-period study after descemetorhexis in patients with Fuchs endothelial corneal dystrophy.	

Department of Ophthalmology Research Division

Research Director **Mathew W. MacCumber, MD, PhD**

Research Manager **Daisy Pacelli, MPH, RN**

Research Coordinator **Parth Brahmbhatt**